stockrow
Friday 6 November 2026
Export CLPT’s income statement to Excel — free account
ClearPoint Neuro, Inc.
CLPT Healthcare Medical Devices
ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- −14.7%
- Free cash flow
- −58.1%
- Total debt
- +74.1%
Quarter to September 2026, against a year earlier
8.60
0.09
−1.04%
Follow CLPT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.32 | 12.73 | 6.62 | 10.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(74.00) | (76.72) | (33.75) | (32.07) | |
P/B ratio |
13.87 | 49.94 | 14.27 | 13.82 | |
Price to Tangible BV |
51.24 | 0.00 | 0.00 | 58.46 | |
EV/Sales |
8.42 | 13.22 | 6.97 | 10.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.91) | (18.52) | (11.00) | (16.33) | |
EV/FCF |
(11.34) | (17.56) | (10.38) | (15.63) | |
Quick Ratio |
5.49 | 3.66 | 4.67 | 4.87 | |
Current Ratio |
6.76 | 4.74 | 5.79 | 5.91 | |
Net Debt/EBITDA |
(1.00) | (2.37) | (1.92) | (0.51) | |
Debt/Assets |
45.10% | 57.91% | 53.14% | 50.21% | |
Debt/Equity |
1.86 | 4.66 | 2.63 | 1.75 | |
Asset Turnover |
0.53 | 0.57 | 0.66 | 0.54 | |
Operating CF/Net income |
0.69 | 0.62 | 0.83 | 1.55 | |
Capex/Depreciation |
(0.08) | (0.15) | (0.56) | (0.06) | |
Interest Coverage |
(4.38) | (7.25) | (6.13) | (6.50) | |
Research and Development Expense of Revenue |
33.28% | 42.57% | 37.29% | 31.10% | |
Selling, General and Administrative Expense of Revenue |
77.62% | 113.25% | 96.57% | 98.10% | |
Intangible Assets out of Total Assets |
0.18 | 0.24 | 0.22 | 0.22 | |
Share Based Compensation of Revenue |
15.57% | 20.87% | 18.29% | 19.03% | |
Graham Net Nets |
(0.05) | (0.05) | (0.07) | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.92%) | (6.61%) | (11.10%) | (6.65%) | |
Free Cash Flow Yield |
(8.93%) | (5.92%) | (10.14%) | (6.45%) | |
Revenue per Share |
0.39 | 0.36 | 0.41 | 0.37 | |
Operating CF per Share |
(0.16) | (0.23) | (0.27) | (0.43) | |
Capex per Share |
0.00 | (0.01) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.24) | (0.29) | (0.43) | |
Cash per Share |
1.49 | 0.97 | 1.20 | 1.62 | |
Shareholders Equity per Share |
0.88 | 0.36 | 0.64 | 0.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.88 | 0.36 | 0.64 | 0.99 | |
Free Cash Flow |
(5.25) | (7.23) | (8.61) | (12.13) | |
Working Capital |
56.85 | 38.62 | 45.40 | 52.84 | |
Capital Expenditures |
(0.14) | (0.21) | (0.64) | (0.05) | |
Net Current Asset Value |
(18.75) | (27.03) | (19.70) | (6.13) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.05 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.01 | 6.33 | 6.16 | 5.63 | |
Average Payables |
0.89 | 1.84 | 1.77 | 1.30 | |
Average Inventory |
8.18 | 7.55 | 7.58 | 7.61 | |
Average Assets |
86.54 | 74.81 | 61.74 | 68.47 | |
Average Common Equity |
21.57 | 15.26 | 19.41 | 26.70 |
Columns are period end dates · fundamentals updated 2 Nov 2026